

North Michael Paul
Form 4
December 14, 2018

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
North Michael Paul

(Last) (First) (Middle)

3854 AMERICAN WAY, SUITE A

(Street)

BATON ROUGE, LA 70816

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMEDISYS INC [AMED]

3. Date of Earliest Transaction
(Month/Day/Year)
12/12/2018

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner
X Officer (give title below) ___ Other (specify below)

Chief Information Officer

6. Individual or Joint/Group Filing(Check Applicable Line)

X Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
			Code	V	Amount	Price	
Common Stock	12/12/2018		M		3,750	A \$ 32.56	25,253 ⁽¹⁾ D
Common Stock	12/12/2018		M		1,875	A \$ 32.56	27,128 ⁽¹⁾ D
Common Stock	12/12/2018		M		1,895	A \$ 46.35	29,023 ⁽¹⁾ D
Common Stock	12/12/2018		S		7,520	D \$ 134.79	21,503 ⁽¹⁾ D
						⁽²⁾	
Common Stock							391 ⁽³⁾ I Through 401(k)

Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (right to buy)	\$ 32.56	12/12/2018		M	3,750	<u>(4)</u> 06/02/2025	Common Stock	3,750
Stock Option (right to buy)	\$ 32.56	12/12/2018		M	1,875	<u>(5)</u> 06/02/2025	Common Stock	1,875
Stock Option (right to buy)	\$ 46.35	12/12/2018		M	1,895	<u>(6)</u> 01/20/2027	Common Stock	1,895

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
North Michael Paul 3854 AMERICAN WAY, SUITE A BATON ROUGE, LA 70816			Chief Information Officer	

Signatures

/s/ Jennifer R. Guckert, pursuant to a power of attorney

12/14/2018

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The total amount of shares beneficially owned includes 761 shares held in an employee stock purchase plan account.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$134.75 to \$135.11, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

(3) The information in this report is based on a plan statement dated as of September 30, 2018.

On June 2, 2015, the reporting person was granted an option to purchase 22,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2016 were met, resulting in vesting of the option as to 5,625 shares (the "2016 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2016 Tranche Options vested on June 2, 2017, one-third of the 2016 Tranche Options vested on June 2, 2018 and the remaining one-third of the 2016 Tranche Options will vest on June 2, 2019, assuming the reporting person remains continuously employed by the Issuer on such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the options.

On June 2, 2015, the reporting person was granted an option to purchase 22,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2017 were met, resulting in vesting of the option as to 5,625 shares (the "2017 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2017 Tranche Options vested on June 2, 2018, one-third of the 2017 Tranche Options will vest on June 2, 2019 and the remaining one-third of the 2017 Tranche Options will vest on June 2, 2020, assuming the reporting person remains continuously employed by the Issuer on each such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the options.

On January 20, 2017, the reporting person was granted an option to purchase 7,577 shares of common stock. The options are subject to time-based vesting conditions. 1,895 of the options vested on January 20, 2018, and the remaining 5,682 options vest ratably on each of January 20, 2019, January 20, 2020 and January 20, 2021, provided that the reporting person remains continuously employed by the Issuer on each such date, subject to pro-rated vesting provisions as provided in the award agreement for the stock option.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.